TARGETING MUC13 TO SENSITISE COLORECTAL CANCER TO THERAPY

Grant number: 1164141 | Funding period: 2019 - 2022

Completed

Abstract

We have found that a naturally occurring mucin molecule, called MUC13, protects the cells lining the bowel wall from death under stress. Colon cancer cells retain MUC13 and use it to protect them from chemotherapy, biological therapy and immunotherapy. In this project we aim to further understand the cellular mechanisms underlying MUC13’s action and focus on capitalising on this knowledge to develop new therapies for colon cancer.

Related publications (2)

MUC1-mediated Macrophage Activation Promotes Colitis-associated Colorectal Cancer via Activating the Interleukin-6/ Signal Transducer and Activator of Transcription 3 Axis.

Yong H Sheng, Julie M Davies, Ran Wang, Kuan Yau Wong, Rabina Giri, Yuanhao Yang, Jakob Begun, Timothy H Florin, Sumaira Z Hasnain, Michael A McGuckin

2022-01-01

BACKGROUND & AIMS: MUC1 is abnormally expressed in colorectal cancer, including colitis-associated colorectal cancer (CAC), but it..

Influence of the MUC1 Cell Surface Mucin on Gastric Mucosal Gene Expression Profiles in Response toHelicobacter pyloriInfection in Mice

Yong H Sheng, Garrett Z Ng, Kim M Summers, Alison L Every, Gareth Price, Sumaira Z Hasnain, Philip Sutton, Michael A McGuckin

2020-07-24

The cell surface mucin MUC1 is an important host factor limiting Helicobacter pylori (H. pylori) pathogenesis in both humans and m..

University of Melbourne Researchers

Mike McGuckin Medicine, Dentistry and Health Sciences